May 21, 2013
1 min read
Save

FDA approves Trulign toric accommodating IOL

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The Trulign toric accommodating posterior chamber IOL has been approved by the U.S. Food and Drug Administration, according to a news release from Bausch + Lomb.

The lens, which corrects for astigmatism and can improve vision across a natural range of focus, is meant for primary implantation in the capsular bag for visual correction of aphakia, as well as postoperative refractive astigmatism secondary to the removal of a cataractous lens, the release said.

It is intended for use in adult patients with or without presbyopia who seek reduction of residual refractive cylinder and increased spectacle independence.

The Trulign, a toric model of Bausch + Lomb’s Crystalens models AT-50SE and AT-52SE, demonstrated improved uncorrected near, intermediate and distance vision in an FDA clinical trial. Its haptic design resulted in 96.1% of lenses rotating fewer than 5° between surgery and at 4- to 6-months post-op, the release said.